内分泌治疗在乳腺癌综合治疗中占有重要的地位,但原发性与继发性耐药是当前内分泌治疗面临的难题.研究证明,雌激素受体通路与各种因子信号通路的交叉效应是导致乳腺癌内分泌耐药的主要机制之一,针对各种通路的靶向治疗药物也成为了热点.许多临床试验结果表明靶向阻断这些信号通路的药物联合内分泌治疗药物可显著提高患者的生存率.本文根据PubMed检索获取相关资料,就近年来与乳腺癌内分泌耐药相关的信号通路及治疗策略研究进展进行综述.%Endocrine therapy plays an important role in the comprehensive treatment of breast cancer,but the primary and secondary resistance is endocrine therapy is currently faced with the problem.Studies have demonstrated that estrogen receptor pathway and the cross effect of various growth factors signaling pathways are endocrine resistance one of the main mechanisms of breast cancer,according to various pathways of targeted therapy drugs has became a hot spot.Many clinical trials have shown that targeting drugs that block these signaling pathways combined with endocrine therapy can significantly improve survival.According to PubMed search for related information,summarized progress on signal pathway and it's treatment strategy associated with endocrine therapy resistance in breast cancer.
展开▼
